Document is current
Any future updates will be listed below
-
Authors
Hernández-Sánchez, Alberto https://orcid.org/0000-0002-6601-3096
González, Teresa
Sobas, Marta
Sträng, Eric
Castellani, Gastone https://orcid.org/0000-0003-4892-925X
Abáigar, María
Valk, Peter J. M. https://orcid.org/0000-0002-8857-9461
Villaverde Ramiro, Ángela https://orcid.org/0000-0002-7337-7218
Benner, Axel
Metzeler, Klaus H. https://orcid.org/0000-0003-3920-7490
Azibeiro, Raúl
Tettero, Jesse M. https://orcid.org/0000-0002-0811-0824
Martínez-López, Joaquín https://orcid.org/0000-0001-7908-0063
Pratcorona, Marta
Martínez Elicegui, Javier https://orcid.org/0000-0001-5294-6162
Mills, Ken I. https://orcid.org/0000-0002-6362-4481
Thiede, Christian https://orcid.org/0000-0003-1241-2048
Sanz, Guillermo https://orcid.org/0000-0002-2767-8191
Döhner, Konstanze https://orcid.org/0000-0002-2261-9862
Heuser, Michael https://orcid.org/0000-0001-5318-9044
Haferlach, Torsten https://orcid.org/0000-0003-0196-2837
Turki, Amin T. https://orcid.org/0000-0003-1347-3360
Reinhardt, Dirk
Schulze-Rath, Renate
Barbus, Martje
Hernández-Rivas, Jesús María
Huntly, Brian https://orcid.org/0000-0003-0312-161X
Ossenkoppele, Gert
Döhner, Hartmut https://orcid.org/0000-0003-2116-5536
Bullinger, Lars https://orcid.org/0000-0002-5890-5510
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (CM23/00101)
Deutsche Forschungsgemeinschaft (FU 356/12-1)
- License Information
-
More Information
Article History
Received: 6 June 2024
Revised: 17 June 2024
Accepted: 27 June 2024
First Online: 4 July 2024
Competing interests
: MS: honoraria from Novartis, Celgene, AOP Orphan, AbbVie. KHM: honoraria from AbbVie, Bristol Myers Squibb, Celgene, Janssen, Novartis, Pfizer, Otsuka; research funding from AbbVie. RA: honoraria from Astellas, Bristol Myers Squibb, Incyte, and Novartis. MP: honoraria from Novartis. CT: co-owner and CEO of AgenDix GmbH and has received lecture fees and/or participated in Ad-Boards from Novartis, Jazz Pharmaceuticals, Astellas, Janssen, Illumina; research funding from Novartis, Bayer. GS: honoraria from Takeda and has participated in Ad-Boards from Novartis, Celgene, Abbvie, Helsinn and Takeda. KD: honoraria from Novartis, Jazz Pharmaceuticals, Abbvie; has participated in Ad-Boards from Novartis, Bristol Myers Squibb, Jazz Pharmaceuticals, Abbvie; research funding from Novartis, Astellas, Agios, Bristol Myers Squibb, Kronos. MH: honoraria from Takeda, Novartis, Janssen, Jazz Pharmaceuticals, Eurocept, Abbvie and has participated in Ad-Boards from Kura Oncology, Glycostem, Daiichi Sankyo, Bristol Myers Squibb, Novartis, Jazz Pharmaceuticals, Abbvie, Pfizer, PinotBio, Roche, Tolremo; research funding from Glycostem, Daiichi Sankyo, Bristol Myers Squibb, Novartis, Jazz Pharmaceuticals, Abbvie, Pfizer, PinotBio, Roche, Astellas, Bayer, BergenBio, Loxo Oncology. TH: current employment at Munich Leukemia Laboratory, with part ownership. ATT: Consultancy for CSL Behring, Maat Pharma, Biomarin and Onkowissen; travel reimbursements from Neovii Biotech. DR: has participated in Ad-Boards from Bristol Myers Squibb, Novartis, Cerus, Medac, EUSA Pharma, Bluebird Bio; research funding from Novartis, BlueBird Bio. RSR: current employment at Bayer Pharma AG. MB: current employment at Abbvie. JMHR: honoraria from Bristol Myers Squibb, Pfizer, Amgen, Celgene, GSK, Novartis; advisory role for Bristol Myers Squibb, Pfizer, Amgen, Celgene, Novartis, Janssen, Roche, Abbvie, AstraZeneca, Beigene, Lilly, Gilead, Takeda, Jazz Pharmaceuticals, Rovi, Incyte; research funding from Bristol Myers Squibb, Celgene, Novartis. BH: honoraria from Pfizer, Bristol Myers Squibb, Novartis; research funding from AstraZeneca. GO: honoraria from Abbvie, Jazz Pharmaceuticals, Astellas, Gilead, Bristol Myers Squibb, Servier, Roche. HD: advisory role for AbbVie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, Bristol Myers Squibb, Celgene, GEMoaB, Gilead Sciences, Janssen, Jazz Pharmaceuticals, Novartis, Syndax; research funding from AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, Jazz Pharmaceuticals, Kronos-Bio, Novartis. LB: honoraria from AbbVie, Amgen, Astellas, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Roche and Sanofi; research funding from Bayer, Jazz Pharmaceuticals.
